Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Drug Profile

Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Alternative Names: 17-beta hydroxysteroid dehydrogenase inhibitors; 17-β HSD type-1 inhibitors; 17β-HSD1 inhibitors; Dual HSD inhibitors; Estradiol dehydrogenase inhibitors; HSD inhibitors programme; HSD programme; HSD-1; HSD17B1 inhibitor

Latest Information Update: 03 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hormos Medical; Solvay Pharmaceuticals; University of Turku
  • Developer Abbott Laboratories; QuatRx Pharmaceuticals
  • Class
  • Mechanism of Action Estradiol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Endometriosis
  • No development reported Breast cancer; Uterine leiomyoma

Most Recent Events

  • 19 Mar 2018 Forendo Pharma plans a phase I trial for FOR 6219 in Endometriosis in second quarter of 2018
  • 25 Jun 2013 Estradiol dehydrogenase inhibitors are still in Preclinical trials for Endometriosis in Finland
  • 25 Jun 2013 Forendo Pharma acquires estradiol dehydrogenase inhibitors programme from Hormos Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top